Erectile Dysfunction (ED) Drugs Market size to grow at a CAGR of 6.1% from 2021 to 2026, Driven by the increasing prevalence of chronic diseases - Technavio

NEW YORK, April 11, 2023 /PRNewswire/ -- The erectile dysfunction (ED) drugs market size is forecast to increase by USD 1.20 billion from 2021 to 2026, at a CAGR of 6.1%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of chronic diseases, rising awareness of ED, and the high prevalence of conditions resulting in ED. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View a Sample Report.

Technavio categorizes the global erectile dysfunction (ED) drugs market Vendor Analysis:

The market landscape of the global ED drugs market is dominated by key vendors. Technavio has extensively analyzed 15 major vendors, including Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, GlaxoSmithKline Plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., VIVUS Inc., and Sanzyme (P) Ltd.

Vendor Offerings -

• Aurobindo Pharma Ltd. - The company offers erectile dysfunction (ED) drugs such as Sildenafil Tablets.
• Bayer AG - The company offers erectile dysfunction (ED) drugs such as Levitra.
• Cipla Ltd. - The company offers erectile dysfunction (ED) drugs such as Stendra.

Data about market vendors have been covered in this report. Download the Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Market Segmentation:

The report extensively covers erectile dysfunction (ED) drugs market segmentation by product (oral drugs, topical drugs, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). 

• The market share growth by the oral drugs segment will be significant during the forecast period. Due to their simple route of administration and high bioavailability, oral medications have the advantage of high patient compliance. Due to their ease of self-administration or administration, these drugs have dominated the market for a long time. In addition, these medications can be purchased over-the-counter, which is a major factor in their substantial market share. 

Get a holistic overview of the market by industry experts to evaluate and develop growth strategies. Download the Sample

Market Dynamics:

Key Drivers:

• One driver fueling growth in the erectile dysfunction (ED) drugs market is the increasing prevalence of chronic diseases.
• Loss of desire, issues with orgasms, and pain during sex are all symptoms of sexual dysfunction disorders, which are more prevalent in women than in men.
• Hormonal factors, irregular menstruation, amenorrhea, a lack of vaginal lubrication, and inability to conceive are some of the factors that contribute to the development of sexual dysfunction disorders in women.
• Diabetes is one example of a chronic illness that can lead to female sexual dysfunction. It is one of the most prevalent chronic diseases worldwide.
• Patients with diabetes might have a few clinical circumstances, including overweight, hypertension, corpulence, metabolic condition, cigarette smoking, and atherogenic dyslipidemia, which are risk factors for sexual brokenness.
• The global ED drugs market is expected to expand during the forecast period as a result of the rising prevalence of these conditions worldwide, which is expected to increase the patient pool with a large number of men and women suffering from sexual dysfunction.

Major Trends:

• The increasing use of drugs causing ED in women is a factor supporting the erectile dysfunction (ED) drugs market share growth.
• Contraceptives, antipsychotics, antiepileptics, and several other drug classes can cause women to experience sexual dysfunction.
• Women's sexual desire decreases when they take drugs such as beta-blockers. Alpha-adrenergic medications, for example, clonidine and prazosin, additionally lessen sexual excitement in women.
• Similar issues arise when taking antidepressants for sexual reasons. Up to 90% of depression patients experience difficulties with orgasm when taking the tricyclic antidepressant clomipramine. Dopamine receptor blockade is the root cause of the majority of ED cases.
• This results in hyperprolactinemia, which then suppresses the hypothalamic-pituitary-gonadal axis and causes hypogonadism in women.
• The use of such drugs will raise the incidence of erectile dysfunction (ED), which will increase the demand for ED medications.

Key Challenges:

• The patent expiry of blockbuster drugs will be a key challenge hampering the erectile dysfunction (ED) drugs market during the forecast period.
• The most popular drugs in the world for erectile dysfunction (ED) have either already expired or are about to expire. VIAGRA (Pfizer), CIALIS (Eli Lilly), LEVITRA, and STAXYN (Bayer) are the most popular drugs on the market.
• For example, the licenses for VIAGRA lapsed in December 2017 in the US. Pfizer and Teva Pharmaceuticals have settled a patent litigation dispute, and in December 2017, the generic version of VIAGRA was made available in the US.
• This was done in order for Pfizer to make up for the losses it suffered as a result of the patent expiry. There are few legal steps involved in manufacturing a generic drug, and production costs are also low.
• As a result, a major obstacle for the market is the emergence of numerous generic versions with lower prices than branded versions.

To get detailed insights about drives, trends, and challenges, buy the report

What are the key data covered in this Erectile Dysfunction (ED) Drugs Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Erectile Dysfunction (ED) Drugs Market between 2022 and 2026
• Precise estimation of the size of the Erectile Dysfunction (ED) Drugs Market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the Erectile Dysfunction (ED) Drugs Market industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Erectile Dysfunction (ED) Drugs Market vendors

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

Related Reports:

The kaposi sarcoma market size has the potential to grow by USD 20.89 million during 2020-2025, and the market's growth momentum will accelerate at a CAGR of 3.10%. This report provides a detailed analysis of the market by treatment type (HAART, chemotherapy, and immunotherapy), geography (North America, Europe, Asia, and ROW), and key vendors. The rising number of organ transplants will drive the global kaposi sarcoma market growth during the estimated period.   

The sarcoma therapeutics market size is expected to increase by USD 1.18 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9%. The report extensively covers sarcoma therapeutics market segmentation by type (soft tissue sarcoma and osteosarcoma) and geography (North America, Europe, APAC, and Rest of the World (ROW)). One of the  factors driving the global sarcoma therapeutics market growth is the patient assistance programs due to the increasing cost of therapeutics for the treatment of various oncology indications. 

Browse for Technavio's Health Care Market Reports       

Table of contents    

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021 

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product 
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Oral drugs - Market size and forecast 2021-2026
• Exhibit 28: Chart on Oral drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Oral drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Oral drugs - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Oral drugs - Year-over-year growth 2021-2026 (%)

• 5.4 Topical drugs - Market size and forecast 2021-2026
• Exhibit 32: Chart on Topical drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Topical drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Topical drugs - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Topical drugs - Year-over-year growth 2021-2026 (%)

• 5.5 Others - Market size and forecast 2021-2026
• Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Product 
• Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 Market opportunity by geography 
• Exhibit 62: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers 

• 8.2 Market challenges 

• 8.3 Impact of drivers and challenges 
• Exhibit 63: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends 

9 Vendor Landscape

• 9.1 Overview 

• 9.2 Vendor landscape 
• Exhibit 64: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 65: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 66: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 67: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 68: Matrix on vendor position and classification

• 10.3 Aurobindo Pharma Ltd. 
• Exhibit 69: Aurobindo Pharma Ltd. - Overview
• Exhibit 70: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 71: Aurobindo Pharma Ltd. - Key offerings

• 10.4 Bayer AG 
• Exhibit 72: Bayer AG - Overview
• Exhibit 73: Bayer AG - Business segments
• Exhibit 74: Bayer AG - Key news
• Exhibit 75: Bayer AG - Key offerings
• Exhibit 76: Bayer AG - Segment focus

• 10.5 Cipla Ltd. 
• Exhibit 77: Cipla Ltd. - Overview
• Exhibit 78: Cipla Ltd. - Business segments
• Exhibit 79: Cipla Ltd. - Key news
• Exhibit 80: Cipla Ltd. - Key offerings
• Exhibit 81: Cipla Ltd. - Segment focus

• 10.6 Eli Lilly and Co. 
• Exhibit 82: Eli Lilly and Co. - Overview
• Exhibit 83: Eli Lilly and Co. - Business segments
• Exhibit 84: Eli Lilly and Co. - Key offerings
• Exhibit 85: Eli Lilly and Co. - Segment focus

• 10.7 Endo International Plc 
• Exhibit 86: Endo International Plc - Overview
• Exhibit 87: Endo International Plc - Business segments
• Exhibit 88: Endo International Plc - Key news
• Exhibit 89: Endo International Plc - Key offerings
• Exhibit 90: Endo International Plc - Segment focus

• 10.8 Futura Medical plc 
• Exhibit 91: Futura Medical plc - Overview
• Exhibit 92: Futura Medical plc - Business segments
• Exhibit 93: Futura Medical plc - Key offerings
• Exhibit 94: Futura Medical plc - Segment focus

• 10.9 GlaxoSmithKline Plc 
• Exhibit 95: GlaxoSmithKline Plc - Overview
• Exhibit 96: GlaxoSmithKline Plc - Business segments
• Exhibit 97: GlaxoSmithKline Plc - Key news
• Exhibit 98: GlaxoSmithKline Plc - Key offerings
• Exhibit 99: GlaxoSmithKline Plc - Segment focus

• 10.10 Pfizer Inc. 
• Exhibit 100: Pfizer Inc. - Overview
• Exhibit 101: Pfizer Inc. - Business segments
• Exhibit 102: Pfizer Inc. - Key news
• Exhibit 103: Pfizer Inc. - Key offerings
• Exhibit 104: Pfizer Inc. - Segment focus

• 10.11 Teva Pharmaceutical Industries Ltd.
• Exhibit 105: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 106: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 107: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 108: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 109: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 VIVUS Inc. 
• Exhibit 110: VIVUS Inc. - Overview
• Exhibit 111: VIVUS Inc. - Business segments
• Exhibit 112: VIVUS Inc. - Key news
• Exhibit 113: VIVUS Inc. - Key offerings
• Exhibit 114: VIVUS Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report 

• 11.2 Inclusions and exclusions checklist
• Exhibit 115: Inclusions checklist
• Exhibit 116: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 117: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 118: Research methodology
• Exhibit 119: Validation techniques employed for market sizing
• Exhibit 120: Information sources

• 11.5 List of abbreviations 
• Exhibit 121: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED